@article{article, title = {{DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)鈥擜 randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.}}, publisher = {{American Society of Clinical Oncology (ASCO)}}, url = {{}}, year = {{2021}}, month = {{2}}, author = {{Niazi T and Williams S and Davis ID and Stockler MR and Martin AJ and Bracken K and Roncolato F and Horvath L and Martin J and Lim TS and Hughes S et al}}, doi = {{10.1200/jco.2021.39.6_suppl.tps266}}, volume = {{39}}, journal = {{Journal of Clinical Oncology}}, issue = {{6_suppl}}, pages = {{TPS266-TPS266}}, note = {{Accessed on 2025/08/11}}}